Skip to main content


July 14, 2022

 2022 Summer Newsletter
2022 Summer Newsletter

Read our latest newsletter here.

July 14, 2022

icon microscope
Webinar: “Progress in Amyloidosis: 2022”

July 2022 Webinar Event

View the recorded webinar below

View Webinar Here

Dr. Zonder will describe recent advances in the management of AL amyloidosis; review approved therapies for ATTR amyloidosis and how they work, and discuss new classes of agents designed to help remove existing amyloid deposits.

June 24, 2022

Intellia therapeutics logo
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., June 24, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced additional positive interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate, NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis.

June 23, 2022

Prothena Logo
AFFIRM-AL Study Protocol Amendment

Prothena has recently implemented an amendment for the AFFIRM-AL Phase 3 study of birtamimab in Mayo Stage IV AL (light chain) amyloidosis which is currently recruiting patients. Birtamimab is an investigational monoclonal antibody designed to target and clear the abnormal protein (amyloid) that can accumulate and cause organ failure in patients with AL amyloidosis.